Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Respirent's Fluticasone Propionate vs GSK's Flovent Diskus
NCT05021887Phase 1Unknown
- Sponsor
- Respirent Pharmaceuticals Co. Ltd.
- Start
- Aug 2021
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone propionate nasal spray in asthma (2 arms), sponsored by Respirent Pharmaceuticals Co. Ltd. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve from time 0 to last measurable concentration. Status: unknown.
02
Drugs
fluticasone propionate nasal spray
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05021887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05021887.